Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127,937 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Yi TW, et al. Among authors: zhang h. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7. Am J Kidney Dis. 2023. PMID: 36889425 Clinical Trial.
Glucocorticoids for IgA nephropathy-pro.
Zhang YM, Lv JC, Wong MG, Zhang H, Perkovic V. Zhang YM, et al. Among authors: zhang h. Kidney Int. 2023 Apr;103(4):666-669. doi: 10.1016/j.kint.2023.01.018. Kidney Int. 2023. PMID: 36948768 No abstract available.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. Kang A, et al. Among authors: zhang h. Diabetes Obes Metab. 2023 Aug;25(8):2151-2162. doi: 10.1111/dom.15091. Epub 2023 May 10. Diabetes Obes Metab. 2023. PMID: 37161691 Clinical Trial.
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J. Rizk DV, et al. Among authors: zhang h. Kidney Int Rep. 2023 Feb 9;8(5):968-979. doi: 10.1016/j.ekir.2023.01.041. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180505 Free PMC article.
IgA nephropathy: the lectin pathway and implications for targeted therapy.
Barratt J, Lafayette RA, Zhang H, Tesar V, Rovin BH, Tumlin JA, Reich HN, Floege J. Barratt J, et al. Among authors: zhang h. Kidney Int. 2023 Aug;104(2):254-264. doi: 10.1016/j.kint.2023.04.029. Epub 2023 May 30. Kidney Int. 2023. PMID: 37263354 Free article. Review.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Charytan DM, et al. Among authors: zhang h. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270. BMJ Open Diabetes Res Care. 2023. PMID: 37311602 Free PMC article. Clinical Trial.
Targeting APRIL in the Treatment of IgA Nephropathy.
Cheung CK, Barratt J, Carroll K, Lafayette RA, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong MG, Zhang H, Perkovic V, Rizk DV. Cheung CK, et al. Among authors: zhang h. Clin J Am Soc Nephrol. 2024 Mar 1;19(3):394-398. doi: 10.2215/CJN.0000000000000338. Epub 2023 Oct 6. Clin J Am Soc Nephrol. 2024. PMID: 37801688 No abstract available.
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Zhang H, et al. Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31. Kidney Int. 2024. PMID: 37914086 Free article. Clinical Trial.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: zhang h. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
127,937 results
You have reached the last available page of results. Please see the User Guide for more information.